Early depemokimab treatment for COPD with type 2 (eosinophilic) inflammation

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a Phase 3, randomized, placebo-controlled trial testing depemokimab as an add-on therapy in adults with moderate-to-severe COPD and evidence of type 2 (eosinophilic) inflammation. Eligible participants have a documented COPD history of at least one year, post-bronchodilator FEV1/FVC < 0.70 with FEV1 between >30% and <80% predicted, and elevated exacerbation risk or symptom burden (for example mMRC ≥2 or CAT ≥15). Current or former smokers with ≥10 pack-years are included, and blood eosinophil counts are used to identify the eosinophilic phenotype. The study compares depemokimab versus placebo on clinical outcomes including exacerbation rates, lung function, symptoms, and safety.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Male or eligible female participants
* Eosinophilic phenotype measured using Blood Eosinophil Count (BEC)
* Moderate to severe COPD, defined as

  * A clinically documented history of COPD for at least 1 year
  * A post-salbutamol Forced expiratory volume in one second (FEV1)/Forced vital capacity (FVC) ratio of less than (\<)0.70 and a post-salbutamol FEV1 greater than (\>)30 percent (%) and \<80% predicted normal values
* Elevated risk for exacerbations, defined as

  * A well-documented history of only 1 moderate COPD exacerbation in the prior 12 months and
  * The presence of risk factors for future exacerbations/deterioration such as:
  * Modified Medical Research Council (mMRC) dyspnea score \>= 2
  * COPD Assessment Test (CAT) \>= 15
  * Post-bronchodilator FEV1 \< 50% predicted
  * Chronic bronchitis
* Smoking status: Current or former cigarette smokers with a history of cigarette smoking of \>=10 pack-years at Screening.
* Dual (Inhaled corticosteroid (ICS)+ Long-acting beta2-adrenergic receptor agonist \[LABA\] or LABA+ Long-acting muscarinic receptor antagonist \[LAMA\]) or triple (ICS+LABA+LAMA) inhaler therapy as assessed by the investigator for at least 3 months
* Body mass index (BMI) \>=16 kilograms per square meter (kg/m\^2)

Exclusion Criteria:

* The Investigator must judge that COPD is the primary diagnosis accounting for the clinical manifestations of lung disease, and clinical manifestations of lung disease where primary diagnosis is not COPD are excluded

  * Participants with a current or prior physician diagnosis of asthma
  * Participants with childhood asthma are permitted, provided that childhood asthma has resolved before 18 years of age and has not recurred
* Other clinically significant lung disease: The Investigator must judge that COPD is the primary diagnosis accounting for the clinical manifestations of the lung disease.
* COPD severity: Participants with more than one moderate exacerbation or severe exacerbation in the past 12 months prior to Visit 1
* COPD stability: Participants with pneumonia, COPD exacerbation, or lower respiratory tract infection within the 4 weeks prior to Visit 1
* Lung resection: Participants with a history of, or plan for lung volume reduction surgery/endobronchial valve procedure
* Pulmonary rehabilitation: Participants in the acute phase of a pulmonary rehabilitation program within 4 weeks prior to Visit 1
* Chronic hypercapnia requiring non-invasive positive pressure ventilation (NIPPV) use including Bi-Level Positive Airway Pressure (BiPAP) or Continuous Positive Airway Pressure (CPAP) are excluded
* Continuous oxygen: Participants requiring oxygen supplementation for COPD

Where it's running

• GSK Investigational Site
  Newport Beach, California, United States Recruiting
• GSK Investigational Site
  Lakewood, Colorado, United States Recruiting
• GSK Investigational Site
  Brandon, Florida, United States Recruiting
• GSK Investigational Site
  Crystal River, Florida, United States Recruiting
• GSK Investigational Site
  Doral, Florida, United States Recruiting
• GSK Investigational Site
  Greenacres City, Florida, United States Recruiting

+71 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Study coordinator: US GSK Clinical Trials Call Center
• Email: GSKClinicalSupportHD@gsk.com
• Phone: 877-379-3718

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Depemokimab for adults with COPD and eosinophilic (type 2) inflammation

  This study will test whether adding depemokimab to usual inhaled therapy can reduce flare-ups and improve outcomes for adults (40–80) with moderate-to-severe COPD and high blood eosinophils.

  Recruiting at 193 sites Phase 3 GlaxoSmithKline · Sheffield, Alabama and 192 other locations · NCT06961214

• Depemokimab — a long‑acting biologic for adults with COPD and type 2 inflammation.

  This trial will test whether adding depemokimab, a long‑acting injectable biologic, reduces flare-ups and improves symptoms in adults with uncontrolled moderate-to-severe COPD who have type 2 inflammation.

  Recruiting at 281 sites Phase 3 GlaxoSmithKline · Bakersfield, California and 280 other locations · NCT06959095

• Ensa?fentrine to help prevent COPD flare-ups in adults on standard care

  This study tests whether ensifentrine (MK-5884) can help prevent moderate or severe COPD exacerbations compared with placebo in adults already receiving standard COPD treatment.

  Recruiting at 7 sites Phase 3 Merck Sharp & Dohme LLC · Hialeah Gardens, Florida and 6 other locations · NCT07874815

• GSK Investigational Medicine GSK3862995B: two formulations in healthy adults

  This early-phase study tests two formulations of GSK3862995B in healthy adults to see how the body handles the drug and whether it is safe and tolerable.

  Recruiting Phase 1 GlaxoSmithKline · Cambridge · NCT07789899

• GSK5784283 added to standard COPD therapy vs placebo in moderate to very severe COPD

  This study tests whether adding GSK5784283 to current COPD treatment reduces the rate of COPD flare-ups in adults with eosinophilic COPD and a history of exacerbations.

  Recruiting at 7 sites Phase 3 GlaxoSmithKline · Doral, Florida and 6 other locations · NCT07780669

• GSK5784283 added to standard COPD care versus placebo in adults with moderate to very severe COPD

  This study tests whether adding GSK5784283 to a patient’s current COPD treatment helps reduce COPD flare-ups compared with a placebo in adults with eosinophilic COPD and a history of frequent exacerbations.

  Recruiting at 8 sites Phase 3 GlaxoSmithKline · Cape Coral, Florida and 7 other locations · NCT07780656

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.